Sale and Shipment of Non-Reportable Patient-Specific Medications by Non-Ohio Licensed Border State Facilities

Updated 4/14/2020

In order to promote social distancing during the COVID-19 outbreak, the State of Ohio Board of Pharmacy issued the following resolution on the sale and shipment of patient-specific, non-reportable dangerous drugs by non-Ohio licensed border state facilities to patients residing in the state.

As used in this guidance:

- **“Non-reportable dangerous drug”** means a dangerous drug, as defined in section 4729.01 of the Revised Code, that is not required to be reported to the Ohio Automated Rx Reporting System for the purposes of reporting wholesale transactions. Therefore, a non-reportable dangerous drug includes all dangerous drugs except for:
  - Controlled substances dangerous drugs; and
  - Dangerous drugs containing gabapentin.

- **“Border state”** means the state of Kentucky, West Virginia, Pennsylvania, Indiana or Michigan.

This guidance is being issued in accordance with a Board resolution adopted on March 2, 2020.

A border state facility that is not licensed in Ohio may sell patient-specific, non-reportable dangerous drugs to Ohio patients if all the following apply:

1. The non-Ohio licensed location is currently licensed in its home state and in good standing. **“In good standing”** means the facility does not have a license, registration or certificate limited, on probation, suspended, or revoked by any public agency or licensing agency. This applies to expired or lapsed licenses that the facility may have held in other states.

2. The facility must offer counseling with every medication dispensed, shipped or sold. The offer shall be made by telephone or in writing on a separate document and shall accompany the medication. A written offer to counsel shall include the hours a pharmacist (or prescriber, if applicable) is available and a telephone number where a pharmacist (or prescriber, if applicable) may be reached. The facility shall have sufficient telephone service to provide access to incoming callers.

3. The dangerous drug sold or shipped was produced by an authorized FDA registered drug manufacturer (i.e. no compounded medications).
4. The facility submits a Border State Shipment Request Form to the Board of Pharmacy prior to shipping any medications to an Ohio patient. Only one request form per unlicensed location must be submitted during the effective period of this guidance. Once the form is reviewed and approved, the facility shall receive temporary authorization from the Board to sell or ship non-reportable, patient-specific dangerous drugs into the state.

*Failure to comply with this resolution will result in an unlicensed entity being found in violation of applicable sections of the Ohio Revised Code.*

This guidance shall remain in effect until June 14, 2020 or when Ohio’s emergency orders are lifted, whichever is earlier.